Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:

• Efficacy of switching to 2-drug oral ART: real-world evidence
• Real-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirine
• Patient selection to reduce risk of virologic failure with switch 
• Regimen-specific switch considerations

Presenters:

Dima Dandachi, MD, MPH, FIDSA, FACP
Associate Professor of Medicine
Division of Infectious Diseases
University of Missouri
Medical Director
HIV Treatment and Prevention Program, MUHC
Medical Director
Boone County Public Health and Human Services
Columbia, Missouri

Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
Honorary Consultant Physician
Barts Health NHS Trust
London, United Kingdom

Link to full program and accompanying slides:
https://bit.ly/3KPN0xb

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.